Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | potassium voltage-gated channel, shaker-related subfamily, member 5 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Echinococcus multilocularis | voltage gated potassium channel | potassium voltage-gated channel, shaker-related subfamily, member 5 | 613 aa | 521 aa | 34.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | kinesin-5 | 0.0109 | 0.1145 | 0.5 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Echinococcus multilocularis | kinesin family 1 | 0.0837 | 1 | 1 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Schistosoma mansoni | voltage-gated potassium channel | 0.0104 | 0.1083 | 0.1248 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0015 | 0 | 0.5 |
Giardia lamblia | Kinesin-5 | 0.0109 | 0.1145 | 0.5 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Echinococcus granulosus | potassium voltage gated channel protein | 0.0104 | 0.1083 | 0.1083 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Loa Loa (eye worm) | hypothetical protein | 0.0104 | 0.1083 | 0.9461 |
Echinococcus granulosus | potassium voltage gated channel subfamily A | 0.0104 | 0.1083 | 0.1083 |
Plasmodium vivax | kinesin-5 | 0.0109 | 0.1145 | 0.5 |
Brugia malayi | Kinesin motor domain containing protein | 0.0109 | 0.1145 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0728 | 0.8678 | 1 |
Loa Loa (eye worm) | kinesin-like protein KLP2 | 0.0109 | 0.1145 | 1 |
Entamoeba histolytica | kinesin, putative | 0.0109 | 0.1145 | 0.5 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Echinococcus multilocularis | potassium voltage gated channel protein | 0.0104 | 0.1083 | 0.1083 |
Brugia malayi | Voltage-gated potassium channel, Shaker-family (KCNA, Kv1-like) alpha-subunit | 0.0104 | 0.1083 | 0.9461 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Schistosoma mansoni | voltage-gated potassium channel | 0.0104 | 0.1083 | 0.1248 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Schistosoma mansoni | kinesin eg-5 | 0.0109 | 0.1145 | 0.1319 |
Echinococcus multilocularis | potassium voltage gated channel subfamily A | 0.0099 | 0.1028 | 0.1028 |
Toxoplasma gondii | kinesin motor domain-containing protein | 0.0109 | 0.1145 | 0.5 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0015 | 0 | 0.5 |
Onchocerca volvulus | 0.0015 | 0 | 0.5 | |
Onchocerca volvulus | 0.0015 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | 0 | Increase in atrial refractory period in surgically instrumented rat electrophysiology model | ChEMBL. | 17125248 |
Activity (functional) | 0 | Increase in atrial refractory period in dog electrophysiology model | ChEMBL. | 17125248 |
Activity (functional) | 0 | Effect on ventricular refractory period in dog electrophysiology model | ChEMBL. | 17125248 |
CL (ADMET) | = 12 ml/min.kg | Clearance in rat | ChEMBL. | 17125248 |
F (ADMET) | = 21 % | Bioavailability in rat | ChEMBL. | 17125248 |
IC50 (functional) | = 60 nM | Antagonist activity at human Kv1.5 channel expressed in CHO cell membrane by HT clamp assay | ChEMBL. | 17125248 |
IC50 (functional) | = 60 nM | Antagonist activity at human Kv1.5 channel expressed in CHO cell membrane by HT clamp assay | ChEMBL. | 17125248 |
IC50 (binding) | > 30000 nM | Binding affinity to hERG potassium channel | ChEMBL. | 17125248 |
IC50 (binding) | > 30000 nM | Binding affinity to hERG potassium channel | ChEMBL. | 17125248 |
Vdss (ADMET) | = 0.8 L/Kg | Volume of distribution in rat | ChEMBL. | 17125248 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.